» Articles » PMID: 18487357

Transforming Growth Factor-beta Signaling Mediates Hypoxia-induced Pulmonary Arterial Remodeling and Inhibition of Alveolar Development in Newborn Mouse Lung

Abstract

Hypoxia causes abnormal neonatal pulmonary artery remodeling (PAR) and inhibition of alveolar development (IAD). Transforming growth factor (TGF)-beta is an important regulator of lung development and repair from injury. We tested the hypothesis that inhibition of TGF-beta signaling attenuates hypoxia-induced PAR and IAD. Mice with an inducible dominant-negative mutation of the TGF-beta type II receptor (DNTGFbetaRII) and nontransgenic wild-type (WT) mice were exposed to hypoxia (12% O(2)) or air from birth to 14 days of age. Expression of DNTGFbetaRII was induced by 20 microg/g ZnSO(4) given intraperitoneally daily from birth. PAR, IAD, cell proliferation, and expression of extracellular matrix (ECM) proteins were assessed. In WT mice, hypoxia led to thicker, more muscularized resistance pulmonary arteries and impaired alveolarization, accompanied by increases in active TGF-beta and phosphorylated Smad2. Hypoxia-induced PAR and IAD were greatly attenuated in DNTGFbetaRII mice given ZnSO(4) compared with WT control mice and DNTGFbetaRII mice not given ZnSO(4). The stimulatory effects of hypoxic exposure on pulmonary arterial cell proliferation and lung ECM proteins were abrogated in DNTGFbetaRII mice given ZnSO(4). These data support the conclusion that TGF-beta plays an important role in hypoxia-induced pulmonary vascular adaptation and IAD in the newborn animal model.

Citing Articles

Caffeine: The Story beyond Oxygen-Induced Lung and Brain Injury in Neonatal Animal Models-A Narrative Review.

Endesfelder S Antioxidants (Basel). 2024; 13(9).

PMID: 39334735 PMC: 11429035. DOI: 10.3390/antiox13091076.


A lactobacilli-based inhaled live biotherapeutic product attenuates pulmonary neutrophilic inflammation.

Nicola T, Wenger N, Xu X, Evans M, Qiao L, Rezonzew G Nat Commun. 2024; 15(1):7113.

PMID: 39160214 PMC: 11333600. DOI: 10.1038/s41467-024-51169-0.


[Risk factors for bronchopulmonary dysplasia in twin preterm infants: a multicenter study].

Fan Y, Zhang Y, Wen H, Yan H, Shen W, Ding Y Zhongguo Dang Dai Er Ke Za Zhi. 2024; 26(6):611-618.

PMID: 38926378 PMC: 11562066. DOI: 10.7499/j.issn.1008-8830.2312005.


Nitric oxide regulation of fetal and newborn lung development and function.

Roberts Jr J Nitric Oxide. 2024; 147:13-25.

PMID: 38588917 PMC: 11148871. DOI: 10.1016/j.niox.2024.04.005.


Inflammation and immunity in the pathogenesis of hypoxic pulmonary hypertension.

Ye Y, Xu Q, Wuren T Front Immunol. 2023; 14:1162556.

PMID: 37215139 PMC: 10196112. DOI: 10.3389/fimmu.2023.1162556.


References
1.
Crossno Jr J, Garat C, Reusch J, Morris K, Dempsey E, McMurtry I . Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am J Physiol Lung Cell Mol Physiol. 2006; 292(4):L885-97. DOI: 10.1152/ajplung.00258.2006. View

2.
Stenmark K, Bouchey D, Nemenoff R, Dempsey E, Das M . Hypoxia-induced pulmonary vascular remodeling: contribution of the adventitial fibroblasts. Physiol Res. 2001; 49(5):503-17. View

3.
Goodman G, Perkin R, Anas N, SPERLING D, Hicks D, Rowen M . Pulmonary hypertension in infants with bronchopulmonary dysplasia. J Pediatr. 1988; 112(1):67-72. DOI: 10.1016/s0022-3476(88)80125-2. View

4.
Hoffmeister H, APITZ J, HOFFMEISTER H, FISCHBACH H . The correlation between blood pressure and morphometric findings in children with congenital heart disease and pulmonary hypertension. Basic Res Cardiol. 1981; 76(6):647-56. DOI: 10.1007/BF01908055. View

5.
Alejandre-Alcazar M, Kwapiszewska G, Reiss I, Amarie O, Marsh L, Sevilla-Perez J . Hyperoxia modulates TGF-beta/BMP signaling in a mouse model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol. 2006; 292(2):L537-49. DOI: 10.1152/ajplung.00050.2006. View